New Blood Markers Could Revolutionize Diabetes Screening for Seniors

New research highlights the effectiveness of two blood markers—glycated haemoglobin (HbA1c) and glycated albumin (GA)—in detecting dysglycemia among older adults. The study, focused on Chinese community-dwelling seniors, suggests both tests offer strong diagnostic accuracy. These findings could influence how clinicians screen for and manage blood sugar disorders in ageing populations. HbA1c measures average blood glucose levels over two to three months and remains a standard tool for diabetes diagnosis. GA, however, reflects shorter-term changes, tracking glucose control over just two to four weeks. Unlike HbA1c, it is less affected by conditions that alter haemoglobin, such as anaemia.

The study found GA to be more sensitive than HbA1c in identifying impaired glucose tolerance. This difference in performance raises questions about current diagnostic cut-offs, which often rely on HbA1c alone. Researchers now urge guidelines committees to account for how each biomarker behaves over time when setting thresholds.

A combined testing approach using both markers could simplify early detection in primary care and community health schemes. The team also called for long-term studies to explore how these biomarkers predict clinical outcomes and track glycemic fluctuations. Future work may examine interactions between GA, HbA1c, and newer markers to refine risk assessments further. The findings underscore the potential of GA alongside HbA1c for more precise dysglycemia screening in older adults. Clinicians may need to adjust diagnostic strategies to incorporate both short- and long-term glucose indicators. Further research will determine whether these biomarkers can improve early intervention and patient outcomes in ageing communities.